CAGNY: Heinz open to Pfizer baby-food morsels

By Dean Best | 24 February 2012

Heinz chief executive Bill Johnson has suggested the US food giant would be interesting in buying any assets that could emerge if Pfizer's infant nutrition unit is sold.

Johnson said Heinz, which has been named as a potential buyer of the business, did not believe buying the whole division would be the "best use of shareholder value". However, speaking at the Consumer Analyst Group of New York investor conference, Johnson said Heinz would look at any assets that could emerge in the wake of any takeover.

"If pieces of that business were to become available for anti-trust reasons or other reasons, we might have an interest. And let me underline might," Johnson said.

Pfizer has yet to officially announce it would sell its infant nutrition unit. However, since the US pharma giant revealed last year it was looking at the options for the business, speculation has grown that it could be offloaded, with Mead Johnson, Danone and Nestle named as potential suitors.

Reuters this week claimed Mead Johnson and Danone are set to join forces and battle for the business with Nestle. Mead Johnson and Danone have declined to comment. Pfizer insisted the Reuters report was "speculation" and said it had to make a decision on what it will do with the unit, which is the world's fifth-largest infant nutrition business.

When Pfizer announced it was looking what to do with the assets, Heinz was also named as a potential suitor. However, Heinz, the world's sixth-largest infant nutrition manufacturer, has not featured in recent speculation.

Johnson said Heinz would not "bet the ranch" on a major transaction in infant formula but would look at smaller deals. He claimed the prices that "have been rumoured" for assets like Pfizer's infant nutrition business did "not make sense" and said he could create more value for investors with deals in condiments and sauces.

"I just don't see the need to take shareholder funds and put them in a category where we are good but not necessarily great," he said. "We're still testing our way through China, doing well but it's still a learning process and our business in Italy still performs well in formula. That's opposed to putting funds some place else that I know can create value through synergies and through growth.

"I wanted to get it clear in the marketplace because it's been bandied about quite a bit. For us to pay the price or to do some kind of structural transaction for that business on a total basis would not create value for the company."

Sectors: Baby food, Emerging markets, Mergers & acquisitions

Companies: Heinz, Pfizer, Mead Johnson, Danone, Nestle

View next/previous articles

Currently reading -

CAGNY: Heinz open to Pfizer baby-food morsels

There are currently no comments on this article

Be the first to comment on this article

Related articles

Focus: Nestle Health Science sneaks under the radar

Nestle's health science division has continued to motor below the radar in the first half of 2012 and the group is confident of a bright future for the unit.

US: Symrise H1 profit up, reaffirms FY guidance

Food ingredients group Symrise has posted an increase in half-year profits, boosted by the company's positive performance in North America.

On the money: Nestle says innovation "key" to growth in mature markets

Nestle has said innovation is key to growth in developed markets where the company says achieving higher sales is "no walk in the park".

Read more on this hot issue

Nestle moves to buy Pfizer's baby food arm

The world's largest food manufacturer beat off reported interest from Danone with a deal worth US$11.9bn. But has the Swiss food giant paid too much?

Welcome to the home of food information, insight & intelligence

Not a member? Join here

Decrease font sizeDecrease font sizeDecrease font size Increase font sizeIncrease font sizeIncrease font size Comment on this article Email this to a friend Print this page